Uterine Neoplasms

Oncology
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
tucatinibPhase 2Small Molecule1 trial
Active Trials
NCT04579380Active Not Recruiting217Est. Apr 2026
Montis Biosciences
Montis BiosciencesBelgium - Leuven
1 program
ERAS protocolN/A1 trial
Active Trials
NCT04063072UnknownEst. Oct 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Pfizertucatinib
Montis BiosciencesERAS protocol

Clinical Trials (2)

Total enrollment: 217 patients across 2 trials

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Start: Jan 2021Est. completion: Apr 2026217 patients
Phase 2Active Not Recruiting

ERAS (Enhanced Recovery After Surgery) Protocol Implementation in Piedmont Region for Hysterectomy.

Start: Sep 2019Est. completion: Oct 2021
N/AUnknown

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space